David Li­u's biotech shoots for $150M+ IPO raise to de­vel­op CRISPR 3.0

Last quar­ter’s biotech IPO raise was the low­est in five years, but the team at Prime Med­i­cine thinks their “holy crap” gene edit­ing tech­nol­o­gy can break the spell.

The Cam­bridge, MA-based com­pa­ny, found­ed by Har­vard bi­ol­o­gist and gene edit­ing pi­o­neer David Liu, pen­ciled in a $151 mil­lion raise on Thurs­day, set­ting the terms for an 8.9 mil­lion-share of­fer­ing at a range of $16 to $18. At the mid­point, the pre­clin­i­cal start­up would be worth $1.7 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER